GlassScriptPhysician profile
James L Miller
NPI 1568443935
$4,207.86
in general payments reported to CMS, 2019-2025
42 companies · $805 in 2025
The $805 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $272 · 2021: $780 · 2022: $669 · 2023: $679 · 2024: $613 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,053 · Education: $43.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.37 |
| Education | $43.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $804.96 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $471.12 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $263.24 | 2019-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $259.63 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $241.68 | 2020-2025 | Takhzyro |
| Amgen INC. | $194.22 | 2019-2024 | Otezla, Repatha |
| Pfizer INC. | $181.96 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $147.34 | 2019-2022 | |
| Csl Behring | $133.54 | 2019-2024 | Haegarda |
| Lilly USA, LLC | $127.13 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $125.89 | 2019-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Vanda Pharmaceuticals INC. | $111.13 | 2025 | Fanapt |
| Novo Nordisk INC | $106.01 | 2019-2021 | |
| Dexcom, INC. | $97.93 | 2022-2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $94.12 | 2025 | Voquezna |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.